plasma kallikrein — Drug Target

All drugs that target plasma kallikrein — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Plasma Kallikrein Inhibitor [EPC] · Plasma Kallikrein Inhibitor

Marketed (5)

• Takhzyro · Dyax Corp · Plasma Kallikrein Inhibitor [EPC] · Neuroscience
  Lanadelumab-flyo binds and inhibits plasma kallikrein, reducing bradykinin generation and controlling angioedema in HAE.
• Orladeyo · Biocryst · Plasma Kallikrein Inhibitor · Neuroscience
  Orladeyo works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms.
• TAKHZYRO · DYAX CORP. · Plasma Kallikrein Inhibitor [EPC] · Neuroscience
• Kalbitor · Dyax Corp. · Plasma Kallikrein Inhibitor [EPC] · Neuroscience
  Kalbitor works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms.
• BEROTRALSTAT HYDROCHLORIDE
  Berotralstat inhibits plasma kallikrein to reduce bradykinin generation and control angioedema in HAE.